UCLA’s Roger Lo awarded $1 million to help prevent cancer relapse

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Roger Lo, a professor of medicine, dermatology and molecular and medical pharmacology at the David Geffen School of Medicine at UCLA, has received a $1 million “All-Star” grant from the V Foundation to develop strategies to prevent relapse in patients with advanced melanoma by targeting drug resistance before it takes root.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

“I don’t think any good cancer center director would be worth their weight in salt if they weren’t worried about something at night,” said Mark Evers, director of University of Kentucky Markey Cancer Center.
Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login